Noteworthy - Pharmaceutical Executive



Biotechnology Innovation and Growth in Israel

December 16, 2013

Israel's diverse population, high-quality healthcare system, and resilience to global financial stress make it a strong partner for R&D, clinical research, and market growth.

Develop Drugs for People, Not Just Bodies

December 1, 2013

A patient-centric approach to drug development delivers the benefits that actually create value, writes Charlotte Vansgaard and Mikkel Brok-Kristensen.

FDA Pursues Delicate Balancing Act

December 1, 2013

The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler.

2013 Pharma and Biotech Financial Report

December 1, 2013

Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better, writes Peter Young.

Executive Profile: United BioSource's Patrick Lindsay

December 1, 2013

For Patrick Lindsay, providing decision support across the full product life cycle is no stretch goal—it's today's fact of life

Complementing Personalized Medicines

November 26, 2013

Mollie Roth discusses how complementary diagnostics can improve disease management and optimize therapy.

Clinical Trial Sponsors Struggle with Data Disclosure Requirements

November 25, 2013

Research sponsors argue that widening access to patient level data from clinical trials will undermine patient privacy and incentives for new drug development.

Pharm Exec Roundtable on Market Access

November 25, 2013

Pharm Exec convenes a diverse panel of experts to identify the key markers of common ground: its time, people, and money against that greatest intangible—hope.

What Does the UK's 'New' PPRS Mean for Value-Based Pricing?

November 20, 2013

Leela Barham ponders the future of VBP in the light of a new PPRS deal between industry and the UK government.


Click here